Approval makes it the first and only therapy in the EU indicated for both acute and chronic hepatitis C, supported by Phase 3 data
Clearing 19 biologics for Europe market
CEO Stéphane Bancel framed the changes as essential to scaling the business
Partnership discussions focus on clinical validation, real-world evidence generation and adoption of indigenous diagnostic technologies across healthcare settings
Dengue, a mosquito-borne viral disease, is emerging as a growing public health threat across Africa
CEPI will commit up to US $50 million to fund preclinical research and Phase 1 clinical trials of Moderna’s mRNA-based vaccine candidate
We have the chance to build an IP estate that goes hand in hand with our generic pharmaceutical strength and build proprietary biological platforms
Lilly will acquire Curevo in a deal worth up to $1.5 billion in cash, including upfront and milestone-based payments.
AAV vectors are widely used in gene therapy for their strong therapeutic potential
If cleared, MAVIRET would become one of the few therapies in the European Union approved to treat both acute and chronic hepatitis C infections
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
